<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360412</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-G000-303</org_study_id>
    <secondary_id>2006-002339-26</secondary_id>
    <nct_id>NCT00360412</nct_id>
  </id_info>
  <brief_title>A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations</brief_title>
  <official_title>A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      Patients who have completed one of the core trials (E2007-E044-301 or E2007-A001-302) and who
      meet inclusion/exclusion criteria will be enrolled and will enter the Titration Phase,
      lasting 4 weeks (weeks 0-3) followed by the Maintenance Phase, lasting 52 weeks (weeks 4-56).
      All patients will receive active study drug. During the Titration Phase, patients will
      receive E2007 2 mg once daily (o.d.) for 2 weeks followed by 4 mg o.d. for 2 weeks. During
      the Maintenance Phase, patients will receive 4 mg o.d. Patients not tolerating the study drug
      at 4 mg, will be allowed to down titrate to 2 mg. Patients not tolerating 2 mg will be
      withdrawn from the study.

      Patients will have visits at 2, 4, 8, 20, 32, 44, and 56 weeks after study entry. In
      addition, a follow-up visit will occur 4 weeks after study treatment has ended (week 60).

      A home diary will be completed in which patients rate themselves as either:

        1. OFF

        2. ON without dyskinesia

        3. ON with non-troublesome dyskinesias

        4. ON with troublesome dyskinesias

        5. Asleep

      These entries will be completed every half hour during the waking day and will be completed
      for 3 consecutive days following the visits at weeks 4, 8, 20, 32 and 44, and three days
      prior to the visits at weeks 56 and 60. At entry into the study (week 0) and at weeks 8, 20,
      32, 44 and 56, the Unified Parkinson's Disease Rating Scale (UPDRS), Clinician's Global
      Impression of Change (CGIC) and Clinical Global Impression of Tolerance (CGIT) will be
      performed.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped due to lack of efficacy.
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study</measure>
    <time_frame>Baseline, Week 0, Week 4, Week 8, Week 20, Week 32, Week 44, Week 56, Week 68</time_frame>
    <description>OFF state is when medication has worn off and is no longer providing benefits with regard to stiffness, slowness, and tremor. This outcome measure was based on data collected through use of a patient diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Daily ON Time (Without Dyskinesias or With Non-troublesome Dyskinesias) (Hours) During Open-label Extension Study</measure>
    <time_frame>Baseline, Week 0, Week 4, Week 8, Week 20, Week 32, Week 44, Week 56, Week 68</time_frame>
    <description>ON state is when medication is providing benefits with regard to stiffness, slowness, and tremor. This outcome measure was based on data collected through use of a patient diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in UPDRS Part II (ADL) Score in OFF State (Hours) During Open-label Extension Study</measure>
    <time_frame>Baseline, Week 0, Week, 8, Week 20, Week 32, Week 44, Week 56, Week 68</time_frame>
    <description>Unified Parkinson's Disease Rating Scale (UPDRS) is a standardized assessment of the symptoms and signs of Parkinson's Disease. Part II assesses activities of daily living (ADL) based on 13 items, such as speech, hygiene, and falling. Participants receive a score of 0-4 points per item, with a higher score indicating more severe symptoms, for a range of total possible scores of 0-52. OFF state is when medication has worn off and is no longer providing benefits with regard to stiffness, slowness, and tremor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in UPDRS Part III (Motor) Score in ON State (Hours) During Open- Label Extension Study</measure>
    <time_frame>Baseline, Week 0, Week 8, Week 20, Week 32, Week 44, Week 56, Week 68</time_frame>
    <description>Unified Parkinson's Disease Rating Scale (UPDRS) is a standardized assessment of the symptoms and signs of Parkinson's Disease. Part III assesses motor activity, based on 14 items, such as gait, facial expression, and rigidity. Participants receive a score of 0-4 points per item, with a higher score indicating more severe symptoms, for a range of total possible scores of 0-56. ON state is when medication is providing benefits with regard to stiffness, slowness, and tremor.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">997</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>E2007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the first two weeks of the study, Patients received 1 x 2mg E2007 tablet. At the week 2 visit, patients who tolerated the 2 mg/day dose were up-titrated to receive 4mg/day (2 x 2 mg E2007 tablets). Patients not tolerating the 4 mg dose were allowed to down titrate to 2 mg. Patients who did not tolerate the 2 mg dose were withdrawn from the study. Patients returned at week 4, if their tolerance to the 4 mg/day dose was acceptable they remained on this dose for the maintenance phase of the study. If at any time their tolerance declined, they were to return for an unscheduled visit and the daily dose was reduced to 2 mg. If at any stage, 2 mg day wass not tolerated, the patient was withdrawn from the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007</intervention_name>
    <arm_group_label>E2007</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female patients with idiopathic PD who have fulfilled the entry criteria to either
        E2007-E044-301 or E2007-A001-302 and have completed that study up to and including the
        final efficacy visit. Patients will not be eligible if they withdrew from the core study
        prior to the final efficacy visit for any reason including lack of efficacy. Patients with
        SAEs which are ongoing or possibly or probably related to the study drug, will not be
        eligible for this study. Patients with ongoing adverse events categorized as severe and
        thought to be related to E2007 should not be entered. Patients with mild or moderate
        adverse events thought to be related to E2007 can be entered to the study if the
        investigator considers it safe.

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Women of child bearing potential unless infertile (including surgically sterile) or
             practicing effective contraception (e.g., abstinence, IUD or barrier method plus
             hormonal method). These patients must have a negative serum or urine B-HCG test at
             their first study visit. These patients must also be willing to remain on their
             current form of contraception for the duration of the study. Postmenopausal women may
             be recruited but must be amenorrhoeic for at least 1 year to be considered of
             non-child bearing potential as determined by the investigator.

          3. Patients with a past (within the past 5 years) or present history of drug or alcohol
             abuse as per DSM IV criteria.

          4. Patients with a past (within one year) or present history of suicidal ideation or
             suicide attempts.

          5. Patients with a past (within one year) or present history of psychotic symptoms
             requiring antipsychotic treatment. Patients may be taking anti-depressant medication,
             however the dose must be stable for 4 weeks prior to the baseline visit. Use of
             anti-psychotic medication including clozapine and quetiapine is prohibited even if the
             indication is for movement disorders.

          6. Patients with unstable abnormalities of the hepatic, renal, cardiovascular,
             respiratory, gastro-intestinal, haematological, endocrine or metabolic systems which
             might complicate assessment of the tolerability of the study medication.

          7. Patients with significantly elevated liver enzymes (abnormal bilirubin or serum
             transaminase levels of more than 1.5 times the upper normal limit).

          8. Medication known to induce the enzyme cytochrome P450 3A4 is prohibited throughout the
             study.

          9. Current or prior treatment (within 4 weeks prior to entry visit) with tolcapone,
             methyldopa, budipine, reserpine, seroquel.

         10. Patients with conditions affecting the peripheral or central sensory system unless
             related to Parkinson's disease (such as mild sensory or pain syndromes limited to OFF
             periods) that could interfere with the evaluation of any such symptoms caused by the
             study drug.

         11. Patients receiving or with planned (next 12 months) deep brain stimulation.

         12. Patients with any condition that would make the patient, in the opinion of the
             Investigator, unsuitable for the study.

         13. Patients with clinically significant ECG abnormalities, including prolonged QTc
             (defined as QTc ≥ 450 msec).

         14. Patients with previous stereotactic surgery (e.g., pallidotomy) for Parkinson's
             disease or with planned stereotactic surgery during the study period.

         15. Patients on pergolide as of April 5, 2007.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Squillacote, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philipps-University Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2006</study_first_submitted>
  <study_first_submitted_qc>August 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2006</study_first_posted>
  <results_first_submitted>October 23, 2012</results_first_submitted>
  <results_first_submitted_qc>January 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 5, 2013</results_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Perampanel (Placebo During Core Study)</title>
          <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
        </group>
        <group group_id="P2">
          <title>Perampanel (Perampanel 2 mg or 4 mg During Core Study)</title>
          <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="333"/>
                <participants group_id="P2" count="664"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="333"/>
                <participants group_id="P2" count="662"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of therapeutic efficacy</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study termination by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="469"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Perampanel (Placebo During Core Study)</title>
          <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
        </group>
        <group group_id="B2">
          <title>Perampanel (Perampanel 2 mg or 4 mg During Core Study)</title>
          <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="333"/>
            <count group_id="B2" value="664"/>
            <count group_id="B3" value="997"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Data comes from previous double-blind core studies (E2007-E044-301) and (E2007-A001-302).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="357"/>
                    <measurement group_id="B3" value="544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="307"/>
                    <measurement group_id="B3" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Data comes from previous double-blind core studies (E2007-E044-301 and E2007-A001-302). Safety Population - All subjects entering the open-label extension study who took at least 1 dose of perampanel</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="428"/>
                    <measurement group_id="B3" value="644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Data comes from previous double-blind core studies (E2007-E044-301 and E2007-A001-302). Safety population.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="320"/>
                    <measurement group_id="B2" value="643"/>
                    <measurement group_id="B3" value="963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study</title>
        <description>OFF state is when medication has worn off and is no longer providing benefits with regard to stiffness, slowness, and tremor. This outcome measure was based on data collected through use of a patient diary.</description>
        <time_frame>Baseline, Week 0, Week 4, Week 8, Week 20, Week 32, Week 44, Week 56, Week 68</time_frame>
        <population>Safety Population- all subjects entering the open-label extension study who took at least 1 dose of perampanel</population>
        <group_list>
          <group group_id="O1">
            <title>Perampanel (Placebo During Core Study)</title>
            <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
          </group>
          <group group_id="O2">
            <title>Perampanel (Perampanel 2 mg or 4 mg During Core Study)</title>
            <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study</title>
          <description>OFF state is when medication has worn off and is no longer providing benefits with regard to stiffness, slowness, and tremor. This outcome measure was based on data collected through use of a patient diary.</description>
          <population>Safety Population- all subjects entering the open-label extension study who took at least 1 dose of perampanel</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="2.158"/>
                    <measurement group_id="O2" value="-0.85" spread="2.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="2.483"/>
                    <measurement group_id="O2" value="-1.16" spread="2.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="2.400"/>
                    <measurement group_id="O2" value="-1.19" spread="2.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.11" spread="2.537"/>
                    <measurement group_id="O2" value="-1.34" spread="2.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="2.663"/>
                    <measurement group_id="O2" value="-1.38" spread="2.676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="2.371"/>
                    <measurement group_id="O2" value="-1.44" spread="2.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="2.607"/>
                    <measurement group_id="O2" value="-0.78" spread="2.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 68</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="2.239"/>
                    <measurement group_id="O2" value="-1.05" spread="1.820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Daily ON Time (Without Dyskinesias or With Non-troublesome Dyskinesias) (Hours) During Open-label Extension Study</title>
        <description>ON state is when medication is providing benefits with regard to stiffness, slowness, and tremor. This outcome measure was based on data collected through use of a patient diary.</description>
        <time_frame>Baseline, Week 0, Week 4, Week 8, Week 20, Week 32, Week 44, Week 56, Week 68</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Perampanel (Placebo During Core Study)</title>
            <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
          </group>
          <group group_id="O2">
            <title>Perampanel (Perampanel 2 mg or 4 mg During Core Study)</title>
            <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Daily ON Time (Without Dyskinesias or With Non-troublesome Dyskinesias) (Hours) During Open-label Extension Study</title>
          <description>ON state is when medication is providing benefits with regard to stiffness, slowness, and tremor. This outcome measure was based on data collected through use of a patient diary.</description>
          <population>Safety Population</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="2.389"/>
                    <measurement group_id="O2" value="0.65" spread="2.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="2.664"/>
                    <measurement group_id="O2" value="0.98" spread="2.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="2.741"/>
                    <measurement group_id="O2" value="0.96" spread="2.801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="2.811"/>
                    <measurement group_id="O2" value="1.14" spread="2.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="2.716"/>
                    <measurement group_id="O2" value="1.05" spread="2.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="2.742"/>
                    <measurement group_id="O2" value="0.98" spread="2.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="2.596"/>
                    <measurement group_id="O2" value="0.02" spread="2.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="2.121"/>
                    <measurement group_id="O2" value="0.21" spread="1.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in UPDRS Part II (ADL) Score in OFF State (Hours) During Open-label Extension Study</title>
        <description>Unified Parkinson’s Disease Rating Scale (UPDRS) is a standardized assessment of the symptoms and signs of Parkinson’s Disease. Part II assesses activities of daily living (ADL) based on 13 items, such as speech, hygiene, and falling. Participants receive a score of 0-4 points per item, with a higher score indicating more severe symptoms, for a range of total possible scores of 0-52. OFF state is when medication has worn off and is no longer providing benefits with regard to stiffness, slowness, and tremor.</description>
        <time_frame>Baseline, Week 0, Week, 8, Week 20, Week 32, Week 44, Week 56, Week 68</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Perampanel (Placebo During Core Study)</title>
            <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
          </group>
          <group group_id="O2">
            <title>Perampanel (Perampanel 2 mg or 4 mg During Core Study)</title>
            <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in UPDRS Part II (ADL) Score in OFF State (Hours) During Open-label Extension Study</title>
          <description>Unified Parkinson’s Disease Rating Scale (UPDRS) is a standardized assessment of the symptoms and signs of Parkinson’s Disease. Part II assesses activities of daily living (ADL) based on 13 items, such as speech, hygiene, and falling. Participants receive a score of 0-4 points per item, with a higher score indicating more severe symptoms, for a range of total possible scores of 0-52. OFF state is when medication has worn off and is no longer providing benefits with regard to stiffness, slowness, and tremor.</description>
          <population>Safety Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="4.035"/>
                    <measurement group_id="O2" value="-0.39" spread="4.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="4.752"/>
                    <measurement group_id="O2" value="-0.60" spread="4.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="4.667"/>
                    <measurement group_id="O2" value="-0.36" spread="5.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="5.018"/>
                    <measurement group_id="O2" value="-0.12" spread="5.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="5.217"/>
                    <measurement group_id="O2" value="-0.25" spread="5.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="5.228"/>
                    <measurement group_id="O2" value="0.38" spread="6.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" spread="0"/>
                    <measurement group_id="O2" value="2.43" spread="5.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in UPDRS Part III (Motor) Score in ON State (Hours) During Open- Label Extension Study</title>
        <description>Unified Parkinson’s Disease Rating Scale (UPDRS) is a standardized assessment of the symptoms and signs of Parkinson’s Disease. Part III assesses motor activity, based on 14 items, such as gait, facial expression, and rigidity. Participants receive a score of 0-4 points per item, with a higher score indicating more severe symptoms, for a range of total possible scores of 0-56. ON state is when medication is providing benefits with regard to stiffness, slowness, and tremor.</description>
        <time_frame>Baseline, Week 0, Week 8, Week 20, Week 32, Week 44, Week 56, Week 68</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Perampanel (Placebo During Core Study)</title>
            <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
          </group>
          <group group_id="O2">
            <title>Perampanel (Perampanel 2 mg or 4 mg During Core Study)</title>
            <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in UPDRS Part III (Motor) Score in ON State (Hours) During Open- Label Extension Study</title>
          <description>Unified Parkinson’s Disease Rating Scale (UPDRS) is a standardized assessment of the symptoms and signs of Parkinson’s Disease. Part III assesses motor activity, based on 14 items, such as gait, facial expression, and rigidity. Participants receive a score of 0-4 points per item, with a higher score indicating more severe symptoms, for a range of total possible scores of 0-56. ON state is when medication is providing benefits with regard to stiffness, slowness, and tremor.</description>
          <population>Safety Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="6.945"/>
                    <measurement group_id="O2" value="-1.87" spread="7.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.17" spread="7.712"/>
                    <measurement group_id="O2" value="-3.08" spread="8.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.48" spread="7.425"/>
                    <measurement group_id="O2" value="-2.72" spread="8.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.86" spread="8.501"/>
                    <measurement group_id="O2" value="-2.84" spread="7.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="8.428"/>
                    <measurement group_id="O2" value="-2.07" spread="9.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="7.770"/>
                    <measurement group_id="O2" value="-0.84" spread="9.428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.00" spread="0"/>
                    <measurement group_id="O2" value="-1.29" spread="6.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were defined as treatment emergent in this study if the start date of the event was on or after the start of study medication in this study. Adverse events that occurred 30 days after the last dose of study drug were 'post-treatment'.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Perampanel (Placebo During Core Study)</title>
          <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
        </group>
        <group group_id="E2">
          <title>Perampanel (Perampanel 2 mg or 4 mg During Core Study)</title>
          <description>Subjects entered this open-label extension study from the double-blind core studies (E2007-E044-301 and E2007-A001-302). Subjects started on perampanel 2mg once daily for two weeks, followed by 4mg once daily for 2 weeks (Titration Phase); Subjects then continued onto the maintenance phase of perampanel 4mg once daily for 2 weeks. Subjects that did not tolerate the study drug at 4mg were allowed to down-titrate to 2mg. Subjects that did not tolerate 2mg were withdrawn from the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Abdomina strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Kyphoscoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Chondrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Metastatic bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Mycosis fungoides</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Parkinson’s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>On and off phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Akinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Bradykinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Hyperkinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Acute Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Pathological gambling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Suicidal attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>On and off phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to early termination, a limited number of subjects (only 2) completed this open-label extension study. The majority of subjects did not reach the scheduled Week 56 assessment. Many outcomes could only be analyzed to Week 68 as a result.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Eisai Inc.</name_or_title>
      <organization>Eisai Call Center</organization>
      <phone>888-422-4743</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

